Advice
Following a re-submission
Bevacizumab (Avastin®) is not recommended for use within NHS Scotland in combination with intravenous fluorouracil/folinic acid or intravenous fluorouracil/folinic acid/irinotecan for first-line treatment of patients with metastatic carcinoma of the colon or rectum.
Bevacizumab, in combination with standard regimens containing fluorouracil and folinic acid or fluorouracil, folinic acid and irinotecan, improved overall and disease-free survival times compared to these standard regimens.
However, the economic case has not been demonstrated.
Download detailed advice78KB (PDF)
Medicine details
- Medicine name:
- bevacizumab (Avastin)
- SMC ID:
- 221/05
- Indication:
- Metastatic colorectal cancer
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 05 June 2006